Look up one drug

Ran-Ramipril HCTZ · DIN 02449439 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2018-05-31 Health Canada: Marketed since 2023-11-04 · brand TARO-RAMIPRIL HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, RAMIPRIL 2.5 MG · company Sun pharma canada inc · schedule Prescription

DIN 02449439: Ran-Ramipril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800266; group id 351; item number 0807; lccId None; manufacturer id RAN Source form: Tab; strength: 2.5mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2242; ministry $0.2242 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449439 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93527

Interchangeable products

Altace HCT · DIN 02283131 · not recorded

Shortage status: resolved shortage (ended 2023-02-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449439

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ramipril HCTZ · DIN 02449447 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2023-12-12 · brand TARO-RAMIPRIL HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, RAMIPRIL 5 MG · company Sun pharma canada inc · schedule Prescription

DIN 02449447: Ran-Ramipril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800267; group id 351; item number 0808; lccId None; manufacturer id RAN Source form: Tab; strength: 5mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3016; ministry $0.3016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449447 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93528

Interchangeable products

Altace HCT · DIN 02283158 · not recorded

Shortage status: resolved shortage (ended 2024-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449447

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ramipril HCTZ · DIN 02449463 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2018-05-31 Health Canada: Marketed since 2023-12-12 · brand TARO-RAMIPRIL HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, RAMIPRIL 5 MG · company Sun pharma canada inc · schedule Prescription

DIN 02449463: Ran-Ramipril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800269; group id 351; item number 0809; lccId None; manufacturer id RAN Source form: Tab; strength: 5mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2872; ministry $0.2872 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449463 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93530

Interchangeable products

Altace HCT · DIN 02283174 · $0.2872

Shortage status: resolved shortage (ended 2025-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449463

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

PMS-Ramipril-HCTZ · DIN 02342154 Manufacturer: Pharmascience Inc.; listing date 2011-03-15 Health Canada: Marketed since 2010-02-03 · brand PMS-RAMIPRIL-HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, RAMIPRIL 10.0 MG · company Pharmascience inc · schedule Prescription

DIN 02342154: PMS-Ramipril-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800268; group id 351; item number 0810; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2634; ministry $0.2634 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02342154 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82765

Interchangeable products

Altace HCT · DIN 02283166 · $0.2634 Ran-Ramipril HCTZ · DIN 02449455 · $0.2634

Shortage status: resolved shortage (ended 2018-05-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342154

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

PMS-Ramipril-HCTZ · DIN 02342170 Manufacturer: Pharmascience Inc.; listing date 2011-03-15 Health Canada: Marketed since 2010-02-03 · brand PMS-RAMIPRIL-HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients RAMIPRIL 10.0 MG, HYDROCHLOROTHIAZIDE 25.0 MG · company Pharmascience inc · schedule Prescription

DIN 02342170: PMS-Ramipril-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800270; group id 351; item number 0811; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2634; ministry $0.2634 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02342170 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82767

Interchangeable products

Altace HCT · DIN 02283182 · $0.2634 Ran-Ramipril HCTZ · DIN 02449471 · $0.2634

Shortage status: resolved shortage (ended 2019-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342170

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Ran-Ramipril HCTZ · DIN 02449455 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2023-12-12 · brand TARO-RAMIPRIL HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, RAMIPRIL 10 MG · company Sun pharma canada inc · schedule Prescription

DIN 02449455: Ran-Ramipril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800268; group id 351; item number 0810; lccId None; manufacturer id RAN Source form: Tab; strength: 10mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2634; ministry $0.2634 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449455 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93529

Interchangeable products

Altace HCT · DIN 02283166 · $0.2634 PMS-Ramipril-HCTZ · DIN 02342154 · $0.2634

Shortage status: resolved shortage (ended 2025-01-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449455

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Ran-Ramipril HCTZ · DIN 02449471 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2023-11-04 · brand TARO-RAMIPRIL HCTZ · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, RAMIPRIL 10 MG · company Sun pharma canada inc · schedule Prescription

DIN 02449471: Ran-Ramipril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800270; group id 351; item number 0811; lccId None; manufacturer id RAN Source form: Tab; strength: 10mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2634; ministry $0.2634 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449471 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93531

Interchangeable products

Altace HCT · DIN 02283182 · $0.2634 PMS-Ramipril-HCTZ · DIN 02342170 · $0.2634

Shortage status: active shortage (reported 2026-03-11, estimated to end 2026-10-16, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449471

Shortage record checked 2026-09-13T08:10:21.292534+00:00